Business
Identifying therapeutic targets in TNBC patients
Identifying therapeutic targets in TNBC patients.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9749F\n Angle PLC\n 25 March 2022\n \n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 25 March 2022\n \n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n \n PARSORTIX SHOWS \n \n \n POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER\n \n \n \n \n \n \n Parsortix system harvests intact CTCs for whole genome sequencing identifying multiple actionable targets \n \n \n \n \n \n Both tumour and CTC samples after pre-surgical chemotherapy show alterations in genes involved in drug resistance\n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, \n is pleased to announce that a leading cancer research institute, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, has published results of a study undertaken in early stage triple negative breast cancer (TNBC) patients undergoing neoadjuvant chemotherapy (NAC; chemotherapy administered before surgery).\n \n \n \n \n \n Researchers used ANGLE's Parsortix® system to isolate circulating tumour cells (CTCs) before, during and after NAC treatment, alongside the collection of primary tumour tissue samples pre- and post-treatment, to analyse for copy number alterations (CNAs), through whole genome sequencing and targeted sequencing, respectively.\n \n \n \n \n \n Using ANGLE's marker-independent Parsortix system to harvest CTCs, followed by automated single-CTC retrieval, the authors identified and analysed both epithelial and non-epithelial CTCs, allowing characterisation of CTCs that would not have been detected by epithelial antibody-based approaches. Analysis of CTCs before, during and after NAC treatment allowed the researchers to track the individual evolution of a patient's TNBC, revealing treatment-induced resistance to the chemotherapy as well as the identification of newly acquired genetic changes that could provide additional treatment options. In two patients, CTCs collected after NAC treatment shared more genomic alterations with the residual tumour, i.e. post-NAC treatment, compared to the primary tumour.\n \n \n \n \n \n This study demonstrates how CNA analysis of CTCs harvested by the Parsortix system, from early stage TNBC patients pre- and post-NAC treatment, has the potential to...